Project Grant W81XWH1110467

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...

Federal Grant Award Summary Merlin Therapeutics Inc. received a $1,256,291 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 27, 2025, with a completion date of July 31, 2027. The award supports the development and advancement of MRL-102, a gene therapy utilizing adeno-associated virus serotype 1 (AAV1) vectors to deliver the...

Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...

The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded Versapeutics Inc. a $2,380,552 federal project grant on September 18, 2023 to conduct toxicology and efficacy studies of their novel antibody therapeutic Versamab-101 for treating spinal cord injury. Versapeutics, a for-profit biotechnology company, will utilize the funding to evaluate the safety profile and determine...

Federal Project Grant Award Summary Savanna Biotherapeutics, Inc. received a $2.98 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award, effective August 1, 2025, and extending through June 30, 2027, supports the development of engineered microglial cell therapy for treating Adult-Onset Leukoencephalopathy with Axonal Spheroids and...

Federal Grant Award Summary Neurogt Inc. received a $699,818 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 8, 2025, with a completion date of April 30, 2027. The company is developing a novel adeno-associated virus (AAV) gene therapy product to treat mucopolysaccharidosis type IIIC (MPS IIIC), a devastating lysosomal storage disease...

Federal Project Grant Award Summary Aquinnah Pharmaceuticals, Inc. received a $1,499,212 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective June 15, 2025, with completion targeted for May 31, 2027. The award supports the development of a novel oral, brain-penetrant therapeutic candidate designed to treat amyotrophic lateral sclerosis...

Federal Grant Award Summary Nostopharma LLC received a $815,584 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, effective July 3, 2025 through June 30, 2027. The award funds preclinical proof-of-concept research for a novel localized drug delivery treatment addressing Fibrodysplasia Ossificans Progressiva (FOP), an ultrarare genetic disease affecting approximately 1 in 1.5-2.0 million live births. The primary deliverable is the...

Federal Grant Award Summary Oligomerix Inc. received a $999,758 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) on August 20, 2025, with a completion date of February 19, 2026. The award funds a 13-week Good Laboratory Practice (GLP) toxicity study of OLX-07010 in Beagle dogs followed by a 4-week recovery period. This preclinical study is designed to support the continued clinical development of OLX-07010, a small molecule drug candidate...

The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $295,923 Project Grant to Kinetiq Therapeutics LLC to conduct preclinical efficacy studies of a subcutaneous enzyme therapy for Fabry disease. The proposed therapy, named BRYSQ, aims to transform the current standard of care by providing a convenient, self-administered treatment that could improve patient quality of life, reduce hospital use, and lower treatment costs compared to the...